

1. Record Nr.	UNINA9910522910603321
Titolo	Urologic oncology : multidisciplinary care for patients // edited by Kelly L. Stratton and Alicia K. Morgans
Pubbl/distr/stampa	Cham, Switzerland : , : Springer, , [2022] ©2022
ISBN	3-030-89891-1
Descrizione fisica	1 online resource (491 pages)
Disciplina	616.99461
Soggetti	Genitourinary organs - Cancer Internal medicine
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di contenuto	Intro -- Contents -- Contributors -- Chapter 1: Creating a Multidisciplinary Clinic -- Introduction -- Historical Perspective -- The Multidisciplinary Clinic at Sidney Kimmel Cancer Center Thomas Jefferson University -- Impact of Multidisciplinary Care -- Establishing a Multidisciplinary Clinic -- Conclusion -- References -- Chapter 2: Supportive and Palliative Care for Genitourinary Malignancies -- Prostate Cancer: Identity -- Vasomotor Symptoms -- Sexual Health and Intimacy -- Kidney Cancer: Variability -- Unique Treatment Toxicity and Adherence -- Adherence and Persistence with Oral Agents -- Decisional Conflict Regarding Cytoreductive Nephrectomy -- Prognostic Uncertainty -- Bladder Cancer: Vulnerability -- Dilemmas in Choice of Urinary Diversion -- Ostomy Care and Management -- Neobladder Care and Management -- Frailty -- Overlapping Supportive Care -- Comprehensive Pain Management -- Antiresorptive Therapy for Palliation of Bone Pain -- Mood Disorders -- Nausea and Vomiting -- Chronic Lower Urinary Tract Symptoms -- Hematuria -- Palliative Care -- References -- Chapter 3: Operationalizing Genetic Testing in the Care of Patients with Prostate Cancer -- Introduction -- Germline Genetic Testing -- Prostate Cancer Genetics -- Genetic Testing Models -- Identifying Patients Appropriate for Genetic Counseling and Testing -- Pre-test Education and Informed Consent -- Test Selection -- Results Delivery -- Somatic Testing -- Cascade Testing -- Identifying

and Overcoming Barriers -- Cementing the Genetic and GU Clinical Team Partnership -- Patient Disparities -- Key Takeaway -- References -- Chapter 4: High-Risk Localized Prostate Cancer -- Defining High-Risk Prostate Cancer -- Treatment -- Observation -- Radiation and ADT -- Duration of ADT -- Combination Radiotherapy -- Surgery for High-Risk Prostate Cancer -- Salvage Therapies for High-Risk Disease.

Treatment of Adverse Pathological Findings Versus Treatment for Failure -- Treatment of Node-Positive Disease -- Surgery After Failure of Radiation Therapy -- Future Directions -- Radiation and Novel Hormone Therapies -- Conclusion -- References -- Chapter 5: Treatment of Metastatic Hormone-Sensitive Prostate Cancer -- Introduction -- Agents Demonstrating Overall Survival Improvement in mHSPC -- Docetaxel -- Abiraterone Acetate -- Novel Anti-Androgens -- Apalutamide -- Enzalutamide -- Agents with No Proven Benefit in mHSPC -- Bisphosphonates -- Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) -- Comparative Efficacy and Sequencing of Agents in mHSPC -- Localized Therapies: Surgery, Radiation to the Primary Tumor, and Metastasis-Directed Therapies in Oligometastatic HSPC -- Emerging Therapies -- Conclusions -- Summary of Key Points -- References -- Chapter 6: Expanding Options for M0 Castration-Resistant Prostate Cancer (CRPC) -- Introduction -- Metastasis-Free Survival (MFS) and Advanced Prostate Cancer Research -- Therapeutic Options in M0 CRPC -- Enzalutamide -- Apalutamide -- Darolutamide -- Agents Under Investigation -- M0 CRPC and Metadata -- Adverse Events and Side Effects in M0 CRPC Treatment -- Managing M0 CRPC in Clinical Practice -- References -- Chapter 7: Immunotherapy for Metastatic Prostate Cancer -- Introduction -- Approved Immunotherapies for Prostate Cancer -- Sipuleucel-T -- Immunotherapy Based on Biomarkers in Prostate Cancer -- Evaluations of Immunotherapy in Unselected Patients -- Ipilimumab -- Pembrolizumab -- Investigating Combinations of Immunotherapy in Prostate Cancer -- Ipilimumab and Nivolumab -- Enzalutamide and PD-1/PD-L1 Inhibitors -- Cabozantinib and Atezolizumab -- Olaparib and Durvalumab -- Future Directions -- Conclusion -- References -- Chapter 8: Advances in Prostate Cancer Imaging -- Introduction.

PET Imaging Techniques for Prostate Cancer -- F-18 Sodium Fluoride PET/CT or PET/MRI Bone Scan (F-18 NaF PET Bone Scan) -- F-18 Fluorodeoxyglucose (FDG) PET -- C-11 Choline or F-18-Choline PET -- F-18 Fluciclovine -- Ga-68 or F-18 Prostate-Specific Membrane Antigen (PSMA) -- F-18 Fluorodehydrotestosterone PET (F-18 FDHT PET) -- Localized Disease/Initial Staging -- Magnetic Resonance Imaging (MRI) -- PET Imaging Probes -- Biochemical Recurrent (BCR) Prostate Cancer -- C-11 Choline or F-18 Choline PET -- F-18 Fluciclovine -- Ga-68 or F-18 Prostate-Specific Membrane Antigen (PSMA) -- Metastatic Prostate Cancer -- Treatment Response -- Biologic Characterization -- Theranostics -- References -- Chapter 9: Bone Health Management -- Introduction -- Physiology of Bone Remodeling -- Evaluation of Bone Mineral Density -- Pathophysiology of Bone Metastasis in Prostate Cancer -- Treatment-Related Bone Loss -- Consequences of Glucocorticoids -- Consequences of Androgen Deprivation Therapy -- Consequences on Bone Metabolism -- Management of Bone Health and Bone Metastases (Tables 9.3 and 9.4 -- Fig. 9.1) -- Bone-Targeted Agents: Bisphosphonates and Denosumab (Table 9.5) -- Prevention and Treatment of Osteoporosis and Fragility Fractures -- Prevention of Skeletal-Related Events -- Safety of Bone-Targeted Agents -- Other Therapies

and Combinations -- Radium-223 Dichloride -- Conclusion --
References -- Chapter 10: Radiotherapy for Advanced Prostate Cancer
-- Introduction -- Palliative Radiotherapy for Advanced Prostate Cancer
-- External Beam Radiotherapy -- Radionuclides -- Radiotherapy
with Oncologic Intent for Advanced Prostate Cancer -- Treatment
of the Primary -- Treatment of Metastatic Lesions -- Radionuclide
Therapy -- Future Indications of Radiotherapy for Advanced Prostate
Cancer -- Conclusion -- References.

Chapter 11: Optimizing Perioperative Treatment for Kidney Cancer --
Introduction -- Complications After Surgery for Localized/Advanced
Renal Cell Carcinoma -- Decision-Making: When to Operate --
Preoperative Risk Stratification -- Assessment of Comorbidity Burden
-- Functional Status -- Frailty -- Nutrition -- Body Composition --
Immune Profile/Inflammation -- Prognostic Models to Convey Risk
in Metastatic Disease -- Laboratory Evaluations -- Comprehensive
Geriatric Assessment -- Medical/Other Consultation -- Perioperative
Optimization -- Counseling/Expectation Setting -- Preoperative
Nutritional Optimization -- Preoperative Exercise Recommendations --
Smoking Cessation -- Systemic Therapy Hold Parameters -- Pre-
surgical Planning -- Intraoperative Considerations -- Postoperative
Optimization -- Immediate Postoperative Period -- Follow-Up
and Cancer Survivorship -- Summary -- References -- Chapter 12:
Surgical Treatment for Metastatic Kidney Cancer -- Introduction --
Cytoreductive Nephrectomy: Historical Perspectives -- Cytoreductive
Nephrectomy in the Era of Targeted Therapy -- Risk Stratification
of Patients Planned to Undergo Cytoreductive Nephrectomy -- The
Timing of Cytoreductive Nephrectomy -- Cytoreductive Nephrectomy
in the Era of Checkpoint Inhibitors -- The Role of CN According
to Current Guidelines -- Metastasectomy for Renal Cell Carcinoma --
Predicting Outcomes After Metastasectomy -- Systemic Therapy After
Metastasectomy -- The Role of Metastasectomy According to Current
Guidelines -- Conclusions -- References -- Chapter 13: Targeted
Therapy for Renal Cell Carcinoma -- Introduction -- Pathophysiology
-- Metastatic Renal Cell Carcinoma -- Frontline Therapy: Combination
Therapy -- Frontline Therapy: Single-Agent Therapy -- Second-Line
Agents: Post-IO Therapy -- Second-Line Agents: Post-TKI Therapy. --
Future Trials.

Localized Renal Cell Carcinoma -- Adjuvant Therapy -- Neoadjuvant
Therapy -- Future Trials -- Novel Agents -- Summary -- References --
Chapter 14: Hereditary Cancer and Genetics in Renal Cell Carcinoma --
Introduction -- Germline Genetic Testing in Kidney Cancer Patients --
Surgical Management of Patients with Localized Hereditary Renal
Tumors -- Implications of Germline Genetics in Management
of Metastatic RCC -- Hereditary Renal Cell Carcinoma Syndromes --
Von Hippel-Lindau Syndrome (OMIM 193300) -- Hereditary
Leiomyomatosis and RCC Syndrome (OMIM 150800) -- Birt-Hogg-
Dube Syndrome (OMIM 135150) -- Hereditary Papillary RCC (OMIM
164860) -- BAP1 Tumor Predisposition Syndrome (OMIM 614327) --
Hereditary Paraganglioma-Pheochromocytoma Syndromes (OMIM
185470) -- Other Hereditary Syndromes with Increased Risk of Renal
Cancer -- Conclusions -- References -- Chapter 15: Immunotherapy
-- Immunotherapy in Patients with Metastatic RCC -- Immunotherapy
in the Adjuvant Setting in Patients with Local/Locally Advanced RCC --
Ongoing Clinical Trials in Metastatic RCC -- Biomarkers
for Immunotherapy in Metastatic Renal Cell Carcinoma -- Conclusions
and Multimodality Care in Renal Cell Carcinoma in the Immunotherapy
Era -- References -- Chapter 16: Evolving Treatment in Non-muscle-
Invasive Bladder Cancer -- Introduction -- Tumor Biology, Genetics,

and Risk Stratification -- Tumor Biology and Genetics -- Risk Stratification -- Endoscopic/Cystoscopic Treatment and Management -- Transurethral Resection of Bladder Tumor (TURBT) -- Surveillance -- Intravesical BCG -- Bacillus Calmette-Guerin (BCG) -- Mechanism of Action -- Induction and Maintenance Regimens -- Risks/Adverse Reactions -- BCG Failure -- Intravesical Chemotherapy -- Chemotherapy Post-TURBT -- Adjuvant Intravesical Chemotherapy -- Low-Risk NMIBC -- Intermediate-Risk NMIBC -- Mitomycin C (MMC). Mechanism of Action.
